Insider Selling: Verona Pharma plc (NASDAQ:VRNA) CEO Sells 3,200 Shares of Stock

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 3,200 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $5.00, for a total transaction of $16,000.00. Following the completion of the transaction, the chief executive officer now owns 15,075,424 shares of the company’s stock, valued at $75,377,120. This trade represents a 0.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

David Zaccardelli also recently made the following trade(s):

• On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total value of $495,428.88.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total value of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total transaction of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The shares were sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total value of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $483,797.28.
• On Friday, October 18th, David Zaccardelli sold 245,784 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total value of $1,076,533.92.

Verona Pharma Stock Down 1.3 %

Verona Pharma stock traded down $0.52 during mid-day trading on Monday, hitting $39.11. The company had a trading volume of 621,587 shares, compared to its average volume of 936,193. Verona Pharma plc has a 12 month low of $11.39 and a 12 month high of $40.76. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The stock’s 50 day moving average price is $34.85 and its two-hundred day moving average price is $25.61. The company has a market capitalization of $3.13 billion, a PE ratio of -20.37 and a beta of 0.46.

Verona Pharma (NASDAQ:VRNA) last announced its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million during the quarter, compared to analyst estimates of $2.31 million. During the same quarter last year, the firm earned ($0.18) earnings per share. As a group, sell-side analysts anticipate that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VRNA. GAMMA Investing LLC raised its holdings in Verona Pharma by 70.6% in the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock worth $38,000 after purchasing an additional 553 shares during the period. CWM LLC purchased a new stake in Verona Pharma in the second quarter worth about $29,000. EMC Capital Management bought a new position in shares of Verona Pharma in the second quarter worth about $38,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after buying an additional 529 shares in the last quarter. Finally, Diversify Advisory Services LLC bought a new position in shares of Verona Pharma during the 3rd quarter valued at approximately $169,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

VRNA has been the subject of several research analyst reports. Wells Fargo & Company increased their price objective on Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Truist Financial boosted their price objective on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group raised their price objective on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, HC Wainwright lifted their price objective on Verona Pharma from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $43.83.

About Verona Pharma

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.